Introduction
Cancer cells are characterized by a great potential to proliferate and evade apoptosis, as well as a capacity to develop blood vessels, invade tissues and metastasize (Hanahan and Weinberg, 2000) . These complex processes reflect intrinsic properties of the malignant cells but are also markedly regulated by non-neoplastic components in the tumour microenvironment (Colotta et al., 2009) . Innate and adaptive immune cells including macrophages, neutrophils, mast cells and lymphocytes are present in most solid tumours. These cells mediate inflammatory responses that are necessary for both tumour progression and the elimination of malignant cells (Coussens and Werb, 2002; Dunn et al., 2004) . For instance, CD8 þ cytotoxic T lymphocytes, interferon-g (IFN-g)-producing T helper 1 (Th1) cells, dendritic cells (DCs) and 'M1' macrophages secreting IL-12 mediate anti-tumour immunity (Dunn et al., 2004; Boon et al., 2006) . In contrast, M2 macrophages, type 2 helper T cells and regulatory T cells (Tregs) have been found to enhance tumour development (Beyer and Schultze, 2006; Roberts et al., 2007; Sica and Bronte, 2007; DeNardo et al., 2009) . Moreover, it has become evident that tumour cells are able to breach the host's immune defences and divert the immune response in order to achieve progressive growth (Dunn et al., 2004) . The driving initiator is still an oncogenic mutation leading to autonomous cell growth. However, several genetic mutations have been demonstrated to lead to the expression of chemokines and cytokines by the malignant cells (Mantovani et al., 2008) . The result is a picture similar to inflammation, with the contribution of this inflammatory milieu to cancer progression.
IL-17, a widely recognized inflammatory cytokine, and the IL-17-producing Th17 cells have recently gained prominence in cancer. Despite the rapid advances in understanding their role in inflammation and autoimmunity, their activity in cancer yields conflicting data. In this review we will focus on the biological functions of IL-17 and discuss the settings in which IL-17 and Th17 cells have been found to exert a pro-or antitumourigenic effect.
IL-17 expression, receptor signalling and biological activities
IL-17 (also called IL-17A) is the prototypic member of the IL-17 family composed of six cytokines, IL-17A-F (Aggarwal and Gurney, 2002; Gaffen, 2004; Huang et al., 2004; Kolls and Linden, 2004) . IL-17 is the hallmark cytokine of Th17 cells and along with IL-17F, with which shares the greatest homology, is also produced by gd T cells, natural killer (NK) T cells, neutrophils and eosinophils (Molet et al., 2001; Starnes et al., 2001; Ferretti et al., 2003; Zhou et al., 2005; Lockhart et al., 2006; Liu et al., 2007) . IL-17A/F signals through IL-17RA, a type I transmembrane protein that is ubiquitously expressed (Moseley et al., 2003; Yang et al., 2008a) . IL-17RA activates mitogen-activated protein kinases and nuclear factor-kB (NF-kB) by tumour necrosis factor receptor-associated factor-6 (TRAF6) and has also been found to physically associate with the NF-kB activator protein (Act1) (Shalom-Barak et al., 1998; Schwandner et al., 2000) . Knockdown of Act1 was subsequently shown to abrogate IL-17-induced inflammatory gene expression as well as NF-kB activation (Chang et al., 2006) .
In vivo A large body of evidence suggests that IL-17A and IL-17F mediate local tissue inflammation by inducing the release of pro-inflammatory and neutrophil-mobilizing cytokines and chemokines. In vivo administration of recombinant IL-17A causes significant accumulation of neutrophils in the bronchioalveolar and joint areas (Hoshino et al., , 2000 Laan et al., 1999; Miyamoto et al., 2003) and leads to disease progression in a syngeneic model of ovarian cancer (Charles et al., 2009) . CXC-chemokine ligand-1 (CXCL1), CXCL2, IL-6 and granulocyte monocyte-colony stimulating factor (GMCSF) have been found to mediate the neutrophil recruitment caused by IL-17A in similar in vivo experimental systems Laan et al., 1999 Laan et al., , 2003 Ferretti et al., 2003; Kolls et al., 2003) . IL-17A has also been found to increase neutrophil elastase and myeloperoxidase activity in vivo (Hoshino et al., 2000) . Interestingly, it has been observed that upon local administration, IL-1b and IL-17A can synergistically increase neutrophil activity but not neutrophil accumulation, suggesting a negative regulatory role for IL-17A in the presence of an inflammatory stimulus promoting the late phase and resolution of inflammation (Hoshino et al., 2000) .
In vitro
In vitro experiments have shown that IL-17A and F stimulate the production of several CXC chemokines, CXCL1, CXCL2 and CXCL5 in mouse fibroblasts and epithelial cells (Fossiez et al., 1996; Laan et al., 1999 Laan et al., , 2001 Kawaguchi et al., 2001; Jones and Chan, 2002; Prause et al., 2004) . They also induce CXCL1, CXCL2, CXCL5 and IL-8 (also known as CXCL8) in human epithelial cells. IL-17A-induced release of CXC chemokines has been shown to involve MAPK and the extracellular signal-regulated kinase (Kawaguchi et al., 2001; Laan et al., 2001; Prause et al., 2004) . In addition to CXC chemokines, IL-17A can induce the release of GCSF and GMCSF (Jones and Chan, 2002; Starnes et al., 2002) as well as the monocyte chemotactic protein-1 and IL-6 in epithelial cells and fibroblasts (Yao et al., 1995; Kawaguchi et al., 2001; Molet et al., 2001) . More interestingly, in response to IL-17A, monocytes isolated from human peripheral blood release TNF-a and IL-1b (Jovanovic et al., 1998) . In contrast, alveolar and peritoneal macrophages fail to produce TNF-a, CXCL2 or IL-6 in response to IL-17A (Kolls et al., 2003) .
Responses to IL-17A can functionally cooperate with responses to other inflammatory cytokines and maximize their biological effects or, as indicated above, in case of IL-1b (for example), modulate inflammatory responses. For example, IL-17A markedly synergizes with TNF-a in inducing GCSF, CXCL1 and IL-8 production by epithelium (Jones and Chan, 2002; McAllister et al., 2005) . Costimulation with IL-17A and IFN-g enhances the IL-8 response in human bronchiolar epithelial cells and increases the expression of intercellular adhesion molecule-1 (Kawaguchi et al., 2001) . In contrast, the Th2 cytokines IL-4 and IL-13 have no additional effect on intercellular adhesion molecule expression (Kawaguchi et al., 2001) . Overall, the response to IL-17 seems to be context dependent. The majority of research work currently focuses on the biological role of IL-17A, and distinctions between the six IL-17 family members in their biological activity are missing. Further studies on the regulation and biological function of these cytokines will benefit our understanding of immune responses.
IL-17 in malignancy
IL-17 has been well studied over the recent years in inflammatory diseases, but what about its role in tumour development and malignant progression? IL-17A expression has been detected in several human tumours, including prostate, breast and gastric cancer (Haudenschild et al., 2002; Steiner et al., 2003; Sfanos et al., 2008; Zhang et al., 2008; Derhovanessian et al., 2009; Horlock et al., 2009) . However, the specific role of IL-17 in cancer is still elusive. IL-17A ectopically overexpressed in murine fibrosarcoma or colon adenocarcinoma cell lines can significantly enhance in vivo tumour growth and increase tumour vascularity (Numasaki et al., 2003;  Table 1 ). It can also stimulate endothelial cell cord formation and upregulate the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), prostaglandin E1 and prostaglandin E2 (Numasaki et al., 2003) . Notably, both cell lines used in those studies are weakly immunogenic. In line with these findings, human cervical cancer cell lines stimulated with recombinant IL-17 upregulate IL-6 and IL-8, and when transfected with IL-17 complementary DNA they show significantly higher tumour growth in athymic nude mice (Tartour et al., 1999) . However, when immunogenic haematopoietic tumour cells overexpressing IL-17 are implanted into syngeneic immunocompetent mice tumour growth is significantly inhibited (Benchetrit et al., 2002) . Although the basis of these differences is not well understood, it appears that IL-17 enhances anti-tumour immunity in immunocompetent mice, but can increase tumour growth in the absence of an adaptive immune response (Martin-Orozco and Dong, 2009) .
More recent studies have evaluated the role of endogenous IL-17 in tumour immunopathogenesis. Wang et al. (2009) showed that growth of the B16 melanoma and the MB49 bladder carcinoma cells is reduced in IL-17 À/À but accelerated in IFN-g À/À mice due to elevated intratumoural IL-17 expression (Table 1) þ T cells showed that IL17R deficiency did not impair their cytotoxic activity or the expression of cytotoxic T lymphocyte-related molecules such as perforin, granzyme B and FasL. Kryczek et al. (2009b) , however, demonstrated a protective role of IL-17 in tumour immunity. They showed, accelerated growth and enhanced lung metastasis of the murine colon cancer cell line MC38 when inoculated in IL-17 À/À mice ( Table 1 ). The underlying mechanism for the increased tumour growth in IL-17-deficient mice was considered to be a reduction in IFN-g-producing NK cells and CD8 þ T cells. Notably, Ngiow et al. (2010) failed to reproduce the MC38-enhanced growth in IL-17 À/À mice and indicated that, although T and NK cells were exerting some host control on tumour development, this was not dependent on IL-17 production. Nevertheless, accelerated tumour growth was also observed in IL-17 À/À mice challenged with the B16-F10 melanoma cell line that colonizes the lung . The discrepancy between these studies and the report by Wang et al. is possibly due to distinct roles of IL-17 in different tumour models mirroring the tissue and context dependency described in inflammatory models.
The majority of the studies investigating the role of IL-17 in tumour development have been conducted on implanted tumour models. The limitation of such models is that they may only show the effects of IL-17 on established tumours that do not grow at their original anatomical sites. The study of IL-17 in genetic, chemical or microbial induced tumour models is limited and is mainly in relation to Th17 immune responses, as will be discussed below. Certainly, further investigations are required to determine the basis of these differences and to clarify the role of IL-17 in the tumour microenvironment.
Tumour-infiltrating Th17 cells
IL-17 is the signature cytokine of Th17 cells. An expanding body of studies indicates that Th17 cells are present at tumour sites (Table 1) . These cells appear to constitute a minor population in human peripheral blood and lymph nodes with no major frequency changes in cancer patients compared with healthy donors (Kryczek et al., 2009a) . There is, however, a strikingly high frequency of tumour-infiltrating IL-17 þ T cells in patients with diverse cancer types, including ovarian and pancreatic cancer (Kryczek et al., 2007 (Kryczek et al., , 2009a Su et al., 2010) . Similar to human models, Th17 cells are found to infiltrate tumours in murine models of cancer while being minimal in peripheral tissues of normal mice (Kryczek et al., 2007) . Moreover, the levels (Kryczek et al., 2007) . The presence of Th17 cells in the tumour microenvironment raises the question about their recruitment, in situ differentiation and, most importantly, their role in tumour immunity.
Phenotypic and tissue-homing features
Tumour-infiltrating Th17 cells exhibit a memory phenotype (CD45RA À CD45RO þ ) and a range of receptors that allow them to traffic in the periphery. They have been found to express high levels of CXCR4 and CCR6 as well as the tissue homing C-type lectin CD161, a molecule found on natural killer cells and CD8 þ T cells (Kryczek et al., 2008 (Kryczek et al., , 2009a Muranski et al., 2008; Martin-Orozco and Dong, 2009) . They also express the gut homing CD49 integrins but not CCR2, CCR5 and CCR7, and therefore have a limited capacity of lymph node trafficking (Kryczek et al., 2009a) . This pattern of receptors may be associated with a selective Th17 cell migration and retention within tumour sites, as high levels of CCL20 and CXCL12 are present in the tumour microenvironment (Zou et al., 2001; Kryczek et al., 2005; Rubie et al., 2006; Aspord et al., 2007; Ghadjar et al., 2009) . Nevertheless, Th17 cells have also been found to produce CCL20 and can therefore promote their own frequency at the tumour site (Muranski et al., 2008) . Kryczek et al. (2009a) further analysed the phenotype of tumour-infiltrating Th17 and reported low levels of the activation markers HLA-DR and CD25, as well as low levels of granzyme B, suggesting that they may not be conventional effector T cells and may not mediate cytotoxic killing through the granzyme B pathway. On the other hand, they reported reduced levels of forkhead box P3 (FoxP3) and the B7-H1 receptor, programmed cell death-1, both of which contribute to immunosuppression in the tumour microenvironment (Kryczek et al., 2009a) . Wilson et al., 2007) . The experimental protocols used to isolate naı¨ve T cells and a TGF-b contamination in the culture system are believed to account for this discrepancy (Manel et al., 2008; Volpe et al., 2008; Yang et al., 2008b) .
TGF-b has a dual function in T-cell polarization by directing the differentiation of both Th17 cells and Tregs pending the polarizing cytokines. Stimulation of naı¨ve T cell with TGF-b alone induces expression of both Foxp3-the transcription factor that guides Treg differentiation-and RORgt (Ivanov et al., 2006; Zhou et al., 2007) . In TGF-b-induced naı¨ve T cells, despite the presence of RORgt, the Foxp3-directed programme of Treg cell differentiation prevails. This is, at least in part, due to Foxp3 counteracting RORgt function (Zhou et al., 2008) . However, in the presence of IL-6, IL-21 or IL-23, Foxp3 activity is inhibited, whereas RORgt is upregulated and stabilized, allowing the progression towards the IL-17 lineage (Zhou et al., 2008) . The signalling pathways initiated after binding of both IL-6 and IL-21 to their receptors in naive CD4 þ T cells are dependent on Stat3 (Zhou et al., 2007) . Stat3 cooperates with RORgt to induce maximum IL-17 expression and optimal Th17 polarization. In addition to IL-17, it induces the transcription of IL-23 and IL-23R on naive T cells and stabilizes the Th17 phenotype (Zhou et al., 2007) .
TNF-a, present within the tumour microenvironment, has also been implicated in Th17 polarization. Although TNF-a is not essential for Th17 differentiation from 
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E Maniati et al naı¨ve T cells, it synergizes with IL-6 and IL-1b to amplify Th17 responses (Veldhoen et al., 2006) . Furthermore, recent studies by our group indicate that TNF-a enhances Th17 differentiation by increasing IL-1R and IL-23R expression (Charles et al., 2009) . More interestingly, microarray data generated from human ovarian cancer revealed significant association between high TNF-a signalling pathway gene expression and expression of genes of the Th17 pathway.
Interaction with the tumour microenvironment Coculture of naı¨ve and memory CD4 þ T cells with tumour cells plus antigen-presenting cells can generate high percentages of Th17 cells (Miyahara et al., 2008) . IL-1b appears to be critical in this setting, whereas IL-6 and IL-23 are important only for the expansion of memory Th17 cells (Miyahara et al., 2008) . Further studies dissect the contribution of tumour-associated macrophages and DCs in Th17 polarization (Kryczek et al., 2009a) . Tumour-associated macrophages and myeloid DCs isolated from human ovarian cancers can polarize memory but not naı¨ve T cells towards a Th17 phenotype. Tumour-associated macrophages express higher levels of IL-1b and IL23p19 and are more efficient in inducing Th17 cells compared with normal macrophages (Kryczek et al., 2009a) . Blocking IL-1b, but not IL-6 or TGF-b, reduced tumour associated macrophage-mediated Th17 induction. Plasmacytoid DCs have minimal effect on Th17 polarization and as tumour-associated macrophages outnumber DCs in cancers they may be the predominant Th17 inducers in the tumour microenvironment (Kryczek et al., 2009a) .
Tumour cells, fibroblasts and endothelial cells release several cytokines and C-C chemokines such as monocyte chemotactic protein-1 (MCP-1), MIP-1a and colony stimulating factor-1, which contribute as major chemoattractants involved in monocyte/macrophage recruitment into the tumour (Coussens and Werb, 2002; Murdoch et al., 2004; Siveen and Kuttan, 2009 ). Th17 cells can in turn favour the recruitment of antigenpresenting cells by releasing CCL20 or inducing the release of this chemokine by resident cells (MartinOrozco et al., 2009) . CCL20 leads to chemotactic recruitment of DCs through CCR6, which might in turn create a positive feedback loop between recruited DCs and Th17 cells promoting their frequency at the tumour site.
Tregs are found at high frequencies in the tumour microenvironment and have been shown to have a critical role in hampering anti-tumour immunity (Zou, 2006) . More interestingly, the Th17 and Treg differentiation programmes are reciprocally related. This suggests a dynamic interaction between Treg and Th17 cells in the tumour microenvironment. Indeed, several studies have shown that naı¨ve and memory Tregs can be induced to secrete IL-17 in the presence of IL-2, IL-1b, IL-6, IL-21 or IL-23 (Xu et al., 2007; Yang et al., 2008b; Ayyoub et al., 2009; Deknuydt et al., 2009; Voo et al., 2009) . IL-2 alone has been shown to mediate the conversion of ovarian cancer-associated Tregs into IL-17 producers . Notably, systemic administration of IL-2 in tumour-bearing mice results in increased numbers of Foxp3 þ Tregs in the tumour and draining lymph nodes, whereas tumourassociated IL-17 þ cells are significantly reduced. Furthermore, IL-2 appears to inhibit the differentiation of Th17 cells from mouse splenocytes in a Stat5-dependent manner but enhance development of Tregs (Kryczek et al., 2007; Leveque et al., 2009) . It is therefore possible that IL-2 has an opposite effect on differentiation of Th17 cells from conventional CD4 þ T cells and Tregs .
In line with the notion of a Treg-Th17 transition at tumour sites, a subpopulation of CD4 þ Foxp3 þ IL-17 þ cells can be detected in humans Voo et al., 2009 ). These cells co-express CD25, Foxp3, IL-17 and RORgt and maintain a suppressive function by a cell-cell contact mechanism (Voo et al., 2009) . Whether these coexpressors derive from Treg or Th17 cells has not been demonstrated, but they appear to represent a transition stage between Treg and Th17 cells. The plasticity of Tregs and the cytokine milieu at tumour sites may, therefore, allow an initial shift towards the IL-17 producing subpopulation and subsequently the development of Th17 cells.
The pro-and anti-tumour activity of Th17 cells
Pro-tumour
Inflammatory processes can promote malignant cell transformation, tumour growth and metastasis (Mantovani et al., 2008) . Th17 cells are characterized by potent pro-inflammatory activities mediated predominantly by their effector cytokines IL-17A/F, IL-21, IL-22 and IL-23. The major pro-tumour roles of Th17 cells rely on their capacity to induce angiogenesis, recruit inflammatory cells and activate tumour-promoting transcription factors ( Figure 2 ). As already mentioned, by acting on stromal cells and fibroblasts, IL-17 induces a wide range of angiogenic factors such as VEGF. Not surprisingly, the levels of IL-17 producing CD4 þ T cells have been positively correlated with microvessel density in tumours (Numasaki et al., 2003) . Interestingly, VEGF induces TGF-b whereas TGF-b can in turn upregulate expression of VEGF receptor on endothelial cells, thereby enhancing their responsiveness to VEGF (Huang and Lee, 2003) .
Human Th17 cells can directly attract neutrophils through the production and release of IL-8 (Pelletier et al., 2010) . This may represent a more efficient mechanism for Th17 cells to rapidly recruit and interact with neutrophils as opposed to the indirect actions of IL-17A/F, which mediate their effect through induction of chemokine secretion by epithelial and endothelial cells (Jones and Chan, 2002) . The same study also shows that Th17 cells are able to modulate neutrophil responses by the release of GMCSF, TNF-a and IFN-g in an IL-17-independent manner. This Th17-neutrophil interaction IL-17 and Th17 in tumour microenvironment E Maniati et al appears to be bidirectional as activated neutrophils can also recruit Th17 in a CCL20/CCR6-dependent manner (Pelletier et al., 2010) . Interestingly, tumour-infiltrating neutrophils are associated with poor prognosis and their capacity to modify tumour growth and invasiveness led to suggestion of a N1/N2 phenotype differentiation similar to the M1/M2 polarization (Haqqani et al., 2000; Sparmann and Bar-Sagi, 2004; Nozawa et al., 2006; Fridlender et al., 2009) . A recent study demonstrates that neutrophil elastase is secreted upon neutrophil activation and can directly induce tumour cell proliferation both in human and mice. Moreover, in a murine model of lung adenocarcinoma, mice lacking neutrophil elastase have markedly decreased tumour burden (Houghton et al., 2010) .
Stat3 has a central role in tumour immunity by promoting pro-oncogenic inflammatory pathways such as NF-kB and Jak pathways and by counteracting Stat1 and NF-kB-mediated anti-tumour Th1 responses . Th17-derived IL-17 induces IL-6 production by malignant as well as tumour stromal cells, which in turn activates Stat3 in both tumour and stromal cells in the tumour microenvironment À/À mice, it is suggested that Stat3 promotes a pro-carcinogenic Th17 response . More recently, the notion of a crucial pro-tumorigenic effect of Th17 cells driven by Stat3 activation is further confirmed in infectioninduced colon carcinogenesis (Wu et al., 2009) .
Anti-tumour
Although tumour-infiltrating Th17 cells appear to have pro-tumour activity, another line of evidence suggests that they may mediate protective anti-tumour immunity (Figure 2) . Muranski et al. (2008) used T-cell receptor transgenic mice specific for a melanoma epitope and polarized CD4 þ T cells towards Th17 in the presence of IL-6 and TGF-b. Upon adoptive transfer into mice with established cutaneous melanoma, these cells mediated effective tumour rejection, better than Th1 polarized cells (Muranski et al., 2008) . Interestingly, their effect was critically dependent on IFN-g whereas depletion of IL-17A and IL-23 had little impact (Muranski et al., 2008) . In a similar study, CD8 þ T cells were skewed to secrete IL-17 in Th17 polarizing conditions and mediated efficient tumour destruction when adoptively transferred into tumour-bearing mice. Again, the response was highly dependent on IFN-g as these cells IL-17 and Th17 in tumour microenvironment E Maniati et al were found to convert into IFN-g producers (Hinrichs et al., 2009) . IL-17 derived from Th17 cells and IFN-g can synergistically induce the secretion of the Th1 type CXCL9 and CXCL10 by tumour cells, which in turn potentially attract effector T cells at the tumour site (Kryczek et al., 2009a) . IFN-g þ IL17 þ T cells have been reported in human tumours and in patients with autoimmune diseases (Kryczek et al., 2008 (Kryczek et al., , 2009a . Additionally, Th17 cells have been reported to divert to Th1 under lymphopenic conditions in mice (Bending et al., 2009; Nurieva et al., 2009) . It is, therefore, speculated that in the tumour microenvironment Th17 cells may be gradually converted into Th1 mediating tumour rejection (Zou and Restifo, 2010) .
A recent study by indicates that tumour-specific Th17 cells play a protective role against tumours by triggering strong CD8 immune responses . Th17 cells lack the ability to traffic to local regional lymph nodes (see above). However, Th17 cell therapy mediated DC recruitment in the tumour tissue in a CCL20/CCR6-dependent manner and further on the presentation of tumour antigens in tumour-draining lymph nodes. The anti-tumour effects of Th17 were abrogated by CCR6 deficiency indicating the importance of the innate mediator. Notably, the Th17 cells retained their cytokine signature upon transfer in tumour-bearing mice and exhibited stronger efficacy than Th1 cells. This finding suggests that tumour-infiltrating Th17 cells may mediate protective immunity indirectly through DC recruitment and cytotoxic T-cell activation.
Beside a pro-or anti-tumour function of Th17 cells, clinical data from anti-CTLA4-treated melanoma patients has indicated that a post-dosing increase in Th17 cells within the peripheral blood mononuclear cell pool associated with treatment-induced toxicity but not with an anti-tumour response (von Euw et al., 2009) . As Th17 cells have been so closely associated with inflammation and autoimmunity, it is particularly important to investigate whether toxicities and responses could be differentially modulated in the context of cancer immunotherapy. The propagated plasticity of T-cell populations is intriguing and the shift from Treg to Th17 cells might be beneficial in the right context.
Conclusions
The role of IL-17 and Th17 cells in the tumour microenvironment is not a clearcut case of pro-or anti-tumourigenicity. The overall impact of IL-17 in cancer may also depend on other cellular sources of the cytokine, such as neutrophils, gd T cells and natural killer T cells. Whether conventional anti-cancer therapies such as chemotherapy and radiotherapy modulate IL-17 secretion and/or Th17 polarization and function is yet unexplored. Understanding the factors that regulate their pro-or anti-tumour activity will allow using the functional properties of this exciting subpopulation for the development of more effective immune therapies in cancer.
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